Weiss Ratings Reiterates "Sell (D-)" Rating for AngioDynamics (NASDAQ:ANGO)

Key Points

• Weiss Ratings has reiterated its "Sell (D-)" rating for AngioDynamics (NASDAQ: ANGO) after recent analysis, indicating ongoing concerns about the company's performance.
• Despite the negative rating from Weiss, some analysts are more optimistic, with three firms issuing "Buy" ratings, and a consensus rating of "Moderate Buy" with an average price target of $19.33.
• AngioDynamics reported quarterly earnings with a revenue increase of 12.1% year-over-year, although it still faced a net loss, highlighting potential challenges ahead.

AngioDynamics (NASDAQ:ANGO - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Several other research firms have also recently issued reports on ANGO. Lake Street Capital began coverage on shares of AngioDynamics in a report on Wednesday, July 16th. They set a "buy" rating and a $24.00 price target for the company. Canaccord Genuity Group increased their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the company a "buy" rating in a report on Friday, October 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 target price on shares of AngioDynamics in a report on Wednesday, July 16th. Finally, Wall Street Zen cut shares of AngioDynamics from a "buy" rating to a "hold" rating in a report on Saturday. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, AngioDynamics currently has a consensus rating of "Moderate Buy" and an average price target of $19.33.

AngioDynamics Trading Up 0.6%

Shares of ANGO traded up $0.07 during mid-day trading on Wednesday, hitting $11.12. 323,331 shares of the company's stock were exchanged, compared to its average volume of 609,821. AngioDynamics has a fifty-two week low of $5.99 and a fifty-two week high of $13.50. The firm has a market capitalization of $458.14 million, a P/E ratio of -14.26 and a beta of 0.78. The business's 50 day moving average is $10.02 and its two-hundred day moving average is $9.78.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. The firm had revenue of $75.71 million during the quarter, compared to analysts' expectations of $72.69 million. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The firm's revenue for the quarter was up 12.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. On average, equities research analysts forecast that AngioDynamics will post -0.37 earnings per share for the current year.

Hedge Funds Weigh In On AngioDynamics

A number of hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC boosted its holdings in shares of AngioDynamics by 28.3% in the 2nd quarter. Squarepoint Ops LLC now owns 85,696 shares of the medical instruments supplier's stock valued at $850,000 after purchasing an additional 18,879 shares during the last quarter. State of Wyoming acquired a new position in shares of AngioDynamics during the 2nd quarter valued at $31,000. Tower Research Capital LLC TRC lifted its holdings in shares of AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock valued at $54,000 after acquiring an additional 4,268 shares in the last quarter. Manatuck Hill Partners LLC lifted its holdings in shares of AngioDynamics by 7.7% during the 2nd quarter. Manatuck Hill Partners LLC now owns 350,000 shares of the medical instruments supplier's stock valued at $3,472,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Massar Capital Management LP acquired a new position in shares of AngioDynamics during the 2nd quarter valued at $278,000. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.